• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

Change in the number of votes in Biotage AB (publ)

Biotage
Download the release

Biotage AB (publ) (“Biotage”) has during May 2025 re-classified 2,611 class C shares to 2,611 ordinary shares in connection with vesting of the long-term incentive plan adopted on the Annual General Meeting 2022 (“LTIP 2022”). The re-classification was carried out by Biotage in order to deliver ordinary shares to participants in LTIP 2022.

Prior to the re-classification, the total number of outstanding shares in Biotage amounted to 80,954,135 and the total number of votes amounted to 80,139,758.3. Through the re-classification, the total number of votes in Biotage has increased by 2,349.9 while the total number of shares remain unchanged. As of today, the last trading day of the month, the total number of registered shares in Biotage amounts to 80,954,135, whereof 80,051,883 are ordinary shares and 902,252 are class C shares held by Biotage. As of today, the number of votes in Biotage amounts to 80,142,108.2, and the registered share capital amounts to
SEK 112,526,247.650000.

Contacts


Frederic Vanderhaegen, President and CEO

Andrew Kellett, CFO

e: ir@biotage.com

About Biotage


Biotage is a global supplier and solutions partner to a wide range of customers within Drug Discovery and Development and Analytical Testing. With expertise in separation and purification technology and leveraging intelligent workflow solutions, the group aims to be the best partner advancing health solutions.

Headquartered in Sweden, Biotage operates globally serving over 80 countries. Biotage is listed on NASDAQ Stockholm (BIOT).
Website: www.biotage.com

This information is information that Biotage is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-05-30 17:00 CEST.

Attachments


Change in the number of votes in Biotage AB (publ)